Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of QB0208-1 in benign prostatic hyperplasia
CTR20244163Phase 2Active
- Sponsor
- Qingbo Huineng
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of QB0208-1 in benign prostatic hyperplasia (BPH) (4 arms), sponsored by Qingbo Huineng. Primary endpoint: Change from baseline in International Prostate Symptom Score total score at Week 4 after first dose. Started Nov 2024; status: active.
02
Drugs
QB0208-1
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on CTR20244163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244163.